• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Baseline low modified health assessment questionnaire (MHAQ) predicts the state of remission estimated by clinical disease activity index and MHAQ at 1 year in tocilizumab-treated rheumatoid arthritis patients.

作者信息

Kawashiri S, Ueki Y, Migita K, Nakamura H, Aoyagi K, Kawakami A

机构信息

Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

出版信息

Clin Exp Rheumatol. 2014 May-Jun;32(3):445. Epub 2014 May 12.

PMID:24850342
Abstract
摘要

相似文献

1
Baseline low modified health assessment questionnaire (MHAQ) predicts the state of remission estimated by clinical disease activity index and MHAQ at 1 year in tocilizumab-treated rheumatoid arthritis patients.基线低改良健康评估问卷（MHAQ）可预测托珠单抗治疗的类风湿关节炎患者1年后根据临床疾病活动指数和MHAQ评估的缓解状态。
Clin Exp Rheumatol. 2014 May-Jun;32(3):445. Epub 2014 May 12.
2
Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.托珠单抗治疗的活动性类风湿关节炎患者3个月时临床疾病活动指数（CDAI）的快速改善预示1年时CDAI结局更佳：一项日常临床实践观察性研究的结果
Clin Exp Rheumatol. 2016 Sep-Oct;34(5):808-812. Epub 2016 Jun 22.
3
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).基线血清骨桥蛋白水平可预测托珠单抗对初治类风湿关节炎患者的临床疗效，但不能预测英夫利昔单抗的疗效：一项为期1年的单中心前瞻性研究（庆应义塾大学首个生物制剂队列研究）
PLoS One. 2015 Dec 23;10(12):e0145468. doi: 10.1371/journal.pone.0145468. eCollection 2015.
4
Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.托珠单抗治疗类风湿关节炎的亚临床炎症：2年的MRI评估
Int J Rheum Dis. 2015 Jan;18(1):108-10. doi: 10.1111/1756-185X.12460. Epub 2014 Oct 7.
5
Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.托珠单抗治疗的类风湿关节炎患者中临床测量方法与德国US7评分的相关性：一项试点研究。
Clin Exp Rheumatol. 2015 May-Jun;33(3):445. Epub 2015 Apr 28.
6
Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.可溶性白细胞介素-6受体的基线水平可预测接受托珠单抗治疗的类风湿关节炎患者的临床缓解：对分子靶向治疗的意义。
Ann Rheum Dis. 2014 May;73(5):945-7. doi: 10.1136/annrheumdis-2013-204137. Epub 2013 Dec 13.
7
Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.采用改良健康评估问卷对早期类风湿关节炎患者的残疾情况进行评估：两年随访后的预后因素。
Clin Exp Rheumatol. 2009 Mar-Apr;27(2):284-91.
8
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.甲氨蝶呤联合托珠单抗治疗对高疾病活动度类风湿关节炎患者获得更好临床结局的重要性：一项观察性队列研究。
Rheumatology (Oxford). 2015 Jan;54(1):113-20. doi: 10.1093/rheumatology/keu302. Epub 2014 Aug 7.
9
Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis.类风湿关节炎患者在接受英夫利昔单抗治疗前后健康评估问卷残疾指数（HAQ-DI）与改良 HAQ（mHAQ）评分的差异。
Mod Rheumatol. 2010 Aug;20(4):337-42. doi: 10.1007/s10165-010-0284-8. Epub 2010 Mar 13.
10
Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.托珠单抗减量用于类风湿关节炎患者缓解期维持治疗的临床经验
Rheumatol Int. 2015 Sep;35(9):1569-70. doi: 10.1007/s00296-015-3243-z. Epub 2015 Mar 13.